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Abstract 
Chitosan (CS), a polysaccharide derived from chitin, the second most abundant polysaccharide, is widely 
used in the medical world because of its natural and nontoxic properties and its innate ability for 
antibacterial and hemostasis effects. In this study, the novel composites containing CS and cellulose 
(CEL) (i.e., [CEL + CS]), which we have previously synthesized using a green and totally recyclable 
method, were investigated for their antimicrobial activity, absorption of anticoagulated whole blood, 
anti-inflammatory activity through the reduction of tumor necrosis factor-α (TNF-α) and interleukin-6 
(IL-6), and the biocompatibility with human fibroblasts. The [CEL + CS] composites were found to inhibit 
the growth of both Gram positive and negative micro-organisms. For examples, the regenerated 100% 
lyophilized chitosan material was found to reduce growth of Escherichia coli (ATCC 8739 and vancomycin 
resistant Enterococcus faecalis (ATCC 51299) by 78, 36, and 64%, respectively. The composites are 
nontoxic to fibroblasts; that is, fibroblasts, which are critical to the formation of connective tissue matrix 
were found to grow and proliferate in the presence of the composites. They effectively absorb blood, 
and at the same rate and volume as commercially available wound dressings. The composites, in both 
air-dried and lyophilized forms, significantly inhibit the production of TNF-α and IL-6 by stimulated 
macrophages. These results clearly indicate that the biodegradable, biocompatible and nontoxic 
[CEL + CS] composites, particularly those dried by lyophilizing, can be effectively used as a material in 
wound dressings. © 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 102B: 1199–
1206, 2014. 
INTRODUCTION 
Chitosan (CS), a linear polysaccharide derived from the N-deacetylation of chitin, which is the second 
most abundant polysaccharide, is known to possess unique properties including wound healing, 
hemostasis, antibacterial activity, and is an effective drug carrier.1-9 These unique properties of CS work 
in concert to synergistically influence three of the four phases of wound healing. In the coagulation 
phase, the hemostatic effect of CS stops hemorrhage, which is generally more of a problem in acute 
than chronic wounds. For wound healing to occur, all cells involved in the coagulation, inflammatory, 
and proliferative phases survive in a moist environment. In a dehydrated or desiccated milieu cells die if 
they dry. CS maintains cellular and tissue viability through its ability to keep the wound moist. Chronic 
wounds such as ulcerations caused by venous and arterial insufficiency of the lower extremities, 
pressure ulcers, and wounds that commonly occur from neuropathy and/or compromised blood 
perfusion in the diabetic foot, generally are inhibited from healing owing to persistent bacterial bio-
burdens during the inflammatory and proliferative phases. Since CS has excellent antimicrobial 
properties, healing of these wounds will occur over more predictable time frames. 
Chitosan is known to have the ability to deliver drugs. CS has the capability to encapsulate, stabilize, and 
deliver drugs that enhance connective tissue matrix growth (i.e., granulation tissue formation) during 
the proliferative phase of healing. Unfortunately, in spite of its clear advantages, there are drawbacks, 
which limit applications of current chitosan‐based dressing products. For example, it is not possible to 
dissolve CS in organic solvents because it has a rigid crystalline structure due to intra- and inter-
molecular hydrogen bonds.10-12 As a consequence, an acid such as acetic acid is required to break 
hydrogen bonds to facilitate dissolution. Subsequent neutralization with a base solution is then needed. 
Such a procedure is not only costly and time consuming, but also may lead to acid induced changes in 
the structure of CS.13, 14 Furthermore, CS has rather poor rheological properties and will undergo 
extensive swelling in water. This makes it structurally too weak to be used by itself in any application. To 
increase the structural strength of CS products, attempts have been made to cross-link chitosan chains 
with a cross-linking agent or convert its functional group through a chemical reaction. In fact, all current 
CS-based biochemical and medical devices are based on these methods.15-19 The rather complicated, 
costly, and multi-step process currently used, that is, it involves the use of environmentally harmful 
chemicals and solvents and man-made polymers to strengthen its structure, is not desirable as it may 
inadvertently alter or remove its unique properties, making the CS-based composite materials less 
biocompatible and toxic. A new method, which can effectively dissolve CS not at high temperature by 
strong acid/base but rather by recyclable “green” solvent and to improve the structural strength of CS 
products not by chemical modification with synthetic chemicals and/or polymers but rather by use of 
naturally occurring biopolymers such as cellulose (CEL), is particularly needed. 
Recently, we have developed a new method, which can offer a solution for this problem.20In this 
method, we exploited advantages of a simple ionic liquid, butyl methylimmidazolium chloride 
(BMIm+Cl−), a green solvent,20 to develop an innovative, simple, pollution-free method to dissolve not 
only CS but also other polysaccharides including CEL without using any acid or base, thereby avoiding 
any possible chemical or physical changes. Secondly, we used only naturally occurring biopolymers, such 
as CEL, as support materials to strengthen structure and expand utilities while keeping the 
biodegradable, biocompatible and anti-infective, and drug carrier properties of CS-based materials 
intact. Using this method, we have successfully synthesized composite materials containing CEL and CS 
with different compositions.20 Preliminary results show that the composite materials obtained have 
combined advantages of their components, namely superior chemical stability and mechanical stability 
(from CEL) and excellent antimicrobial properties (from CS). The [CEL + CS] composite materials inhibit 
growth of a wider range of bacteria than other CS-based materials prepared by conventional methods. 
Specifically, we found that over a 24 h period, the [CEL + CS] composite materials substantially inhibited 
growth of bacteria such as methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant 
Enterococcus (VRE), Staphylococcus aureus, and Escherichia coli.20 
To evaluate the suitability of these novel [CEL + CS] composites for use as wound dressing material, we 
systematically investigated their antimicrobial activity, ability to absorb anti-coagulated whole blood, 
anti-inflammatory activity through the reduction of tumor necrosis factor‐α (TNF‐α) and interlukin‐6 (IL‐
6), and their biocompatibility with human fibroblasts. The results of our investigation are reported 
herein. 
MATERIALS AND METHODS 
Materials 
The preparation and complete characterization of the [CEL + CS] composite materials used in this study 
was described in our previous publication.20 Minimal essential medium (MEM), 10% Fetal Bovine Serum 
(FBS), and gentamicin were obtained from Atlanta Biologicals, Lawrenceville, GA. CellTiter 96® aqueous 
non-radioactive cell proliferation assay was obtained from Promega, Madison, WI. One Percent 
Penicillin–Streptomycin and phorbol 12-myristate 13-acetate (PMA) were obtained from VWR, Radnor, 
PA. The enzyme-linked immunosorbent assay (ELISA) kit was from R&D Systems, Minneapolis, MN and 
was used according to the manufacturer's instructions. Images of the fibroblasts and macrophages were 
taken with an Olympus microscopic camera using CellSens Imaging Software (Olympus, Center Valley, 
PA). Kendall – Curity AMD gauze sponges, 8 and 12 ply (Covidien, Mansfield, MA), Promogran matrix 
wound dressing (Johnson & Johnson, New Brunswick, NJ), Aquacel and DuoDERM CGF (ConvaTec, 
Princeton, NJ), Allevyn adhesive (Smith + Nephew, Andover, MA) are wound dressing that were 
purchased commercially. 
Bactericidal activity 
Bacterial killing assays were performed in the presence and absence of the composites with varying 
concentrations of CS and CEL. The bacterial strains used in this protocol included Escherichia coli (ATCC 
8739), Staphylococcus aureus (ATCC 25923), methicillin resistant S. aureus (ATCC 33591), and 
vancomycin resistant Enterococcus faecalis (ATCC 51299). The strains were maintained on blood agar at 
4°C. According to a modified protocol from Pinto et al.,21 bacterial cells were grown in nutrient broth for 
18–20 h at 37°C with agitation. The cells were diluted in fresh medium and incubated for 24 h at 37°C in 
the presence of the composites. Serial dilutions of the bacteria were plated onto nutrient agar and 
incubated for 24 h. Bacterial colony forming units (CFUs) were quantified and compared to bacteria 
grown in the absence of composites. 
Blood absorption 
The capability of the commercially available wound dressings [Figure 1(C)] and [CEL + CS] composites to 
absorb blood and the rate of absorption were examined using the procedure reported by Terrill et 
al.22 In brief, each type of composite or dressing was premeasured and preweighed before testing. The 
composites or the dressing materials were then placed in a square petri dish with approximately 30 mL 
of whole blood donated by the Zablocki VA Medical Center, Milwaukee, WI. The dishes were incubated 
at 37°C. Before being weighed, the material was suspended above the dish for 30 s to release all 
unabsorbed blood. The composites and dressings were weighed at 30 min and 24 h. The amount of 
blood absorbed was then calculated as g/100 cm2. 
 
Figure 1 Comparison of blood absorbed over time by air‐dried and lyophilized [CEL + CS] composites (A and B) and 
commercially available wound dressing materials (C) at 30 min (red) and 24 h (blue). At least three independent 
experiments were performed. [Color figure can be viewed in the online issue, which is available 
at wileyonlinelibrary.com.] 
Fibroblast adherence and growth 
The adherence and growth of fibroblasts in the presence of the [CEL + CS] composites were assessed 
with modifications from Kloth et al.23 Essentially, human fibroblasts (ATCC CRL-2522) were grown in 
minimal essential medium (MEM) supplemented with 10% FBS and 0.25 mg/mL gentamicin according to 
ATCC guidelines until at least the 2nd passage. Cells were seeded into the wells containing membrane 
composites at a concentration of 8 × 104cells/mL per well. Cells were imaged by an Olympus microscope 
camera using CellSens Imaging Software. 
Viability assay 
The proliferation of fibroblasts was assessed by the CellTiter 96® aqueous non‐radioactive cell 
proliferation assay by the reduction of MTS [3‐(4,5‐dimethylthiazol‐2‐yl)−5‐(3‐
carboxymethoxyphenyl)−2‐(4‐sulfophenyl)−2H‐tetrazolium] into a formazan product. The protocol was 
modified according to Silva et al. In brief, the MTS reagent was added to each well in a 5:1 ratio with the 
fresh noncolored culture medium.24 The cells were incubated at standard culture conditions for 4 h and 
the optical density (490 nm) was measured. 
Cell culture 
The human monocytic cell line THP-1 (ATCC TIB-202) was cultured in RPMI-1640 medium supplemented 
with 10% FBS and 1% Penicillin–Streptomycin. Stimulation and differentiation of monocytes to 
macrophages was performed by adding 0.2 µM phorbol 12-myristate 13-acetate (PMA) to the medium. 
The cell line was maintained under 5% CO2 humidified atmospheric conditions in a 37°C incubator. 
Cytokine measurement 
The cultured monocytes were grown and diluted to a concentration of 5 × 105 cells/mL. A 24-well tissue 
culture plate was seeded with 1.6 mL of cells and [CEL + CS] composites were added to appropriate 
wells. TNF‐α and interleukin‐6 (IL‐6) levels were measured and data analyzed using an ELISA kit 
according to manufacturer's instructions. Images of the macrophages were taken with an Olympus 
microscopic camera using CellSens Imaging Software. 
Statistical analysis 
Statistics on data were performed with Microsoft Excel and StatPlus® software. Data are 
presented ± standard error of the mean. A p value of ≤ 0.05 was considered significant. 
RESULTS AND DISCUSSION 
Chitosan has proven to have efficient antimicrobial activity.24-26 It has been widely used in the food and 
agricultural industries and in wound dressings because of its characteristic antibacterial activity toward 
both Gram positive and Gram negative organisms.27 To assess the antimicrobial abilities of the [CEL + CS] 
composites, bacteria were grown in the presence of the composites and then plated out onto growth 
agar and measured by the amount of colonies formed compared to a standard growth control. The 
results for the percent growth reduction of the different composites are shown in Table 1. It is evident 
that there is bactericidal activity with the lyophilized 100% chitosan sample (Chitosan L) for all the 
bacteria except for S. aureus, with the greatest effect on E. coli and VRE. The 50% composite had the 
greatest effect on S. aureus. Even though there was a bactericidal effect on MRSA with lyophilized 100% 
CS, 50%, and 29% [CS + CEL] composites; the standard deviations associated with each growth reduction 
value was relatively high. It seems, therefore, that statistically, there was no significant growth reduction 
among all of the composites for MRSA. Since errors associated with results obtained for effect on 
P. aeruginosa are relatively large the results are inconclusive. This may be due to the fact that it was 
found that the inner surface of the test tube used in this assay was found to be coated with biofilm. This 
is hardly surprising because this microbe is known to be a strong producer of biofilms, and as described 
below, the chitosan composites were found to have no effect on bacterial biofilms. 
Table 1. Percent Growth Reduction of Bacteria Growth in the Presence of Chitosan Composites  
100% Chitosan 100% Chitosan (L) 50% Chitosan 29% Chitosan 
S. aureus 35 (±30) −5.3 (±76) 70 (±11) 54 (±38) 
MRSA −0.4 (±1) 36 (±42) 2 (±21) 14 (±14) 
VRE −21 (±65) 64 (±35) 30 (±26) 38 (±19) 
E. coli 15 (±34) 78 (±17) 9 (±23) 39 (±31) 
P. aeruginosa −41 (±6.3) 42.5 (±71) −218 (±22) 80 (±52) 
 
The bacteria used in this study were selected because they were found to have the highest morbidity 
and mortality associated with wound infections. Similar effect was also observed by Burkatovskaya and 
co-workers who reported that Chitosan acetate has greater effect against micro-organisms both in 
vitro and in a mouse wound model than other types of nonchitosan wound treatments.27-29 Ignatova et 
al.30, 31 demonstrated that electrospun mats of quarternized chitosan killed bacteria, especially S. 
aureus and E. coli within 2 h. Modified chitosan material, such as quarternized or those supplemented 
with silver nanoparticles were reported to have more of an effect with micro-organisms than chitosan 
alone.21, 30, 31 Cai et al.32 showed an inhibition of E. coli growth, but not with S. aureus with a chitosan/silk 
fibroin composite. Also, chitosan–dextran hydrogel composite has shown to exhibit antimicrobial 
activity against Staphylococcus, Streptococcus, Clostridium, and E. coli,33 and Wu et al.34 showed a 
chitosan dose dependent bacteriostatic effect on S. aureus and E. coli with their chitosan/cellulose blend 
of composites. 
In this study, we used chitosan composites in their natural state or in a composite with cellulose. 
Modifications to chitosan material can be expensive, potentially toxic, and complicated to produce. To 
be able to use chitosan in its natural state in a wound dressing, the benefits with respect to 
biodegradability, toxicity, and production would be advantageous. Results obtained in this study clearly 
indicate that the novel [CEL + CS] composite previously synthesized by us can effectively kill both Gram 
positive (S. aureus and VRE) and Gram negative (E. coli and P. aeruginosa) bacteria over a period of 24 h. 
Clearly, their antimicrobial activities are superior to those reported for composites made from chitosan 
and man-made polymers. Bacteriostatic and bactericidal properties are known to be important for 
wound healing applications in preventing infection and even possible sepsis. These effects of the 
chitosan composites on the wound pathogens illustrate their great potential as components in wound 
dressings. 
Subsequently, bacterial biofilms were assessed for a change in metabolic activity in the presence of the 
chitosan material. It was found that after 24 h, the chitosan composites did not decrease the metabolic 
activity compared to the (no-chitosan) control biofilm (data not shown). It is hardly surprising to observe 
lack of effect of the chitosan composites on biofilms because biofilms are known to envelop bacteria 
with a polymeric matrix that prevents topical antibiotics and antiseptic agents from reaching the 
infecting microbes.35 In fact, currently, all available broad spectrum antimicrobial agents that are 
typically used on chronic wounds (e.g., sodium hypochlorite, cadexomer iodine, chlorhexidine, and 
hydrogen peroxide) are not able to eradicate biofilms. Of interest is the recent report to indicate that 
low intensity electric fields can completely override the inherent resistance of biofilm bacteria to 
biocides and antibiotics. Experiments are now in progress to investigate this possibility.36 
An ideal wound dressing material should maintain a delicate balance of absorption of fluids with the 
ability to maintain a moist healing environment for proper tissue repair. The results obtained for 
absorption of whole blood by air‐dried [CEL + CS] composites, lyophilized [CEL + CS] composites and 
commercial dressings including Allevyn, Aquacel, Curity Gauze, Promogram, and DuoDerm over 30 min 
and 24 h are shown in Figure 1(A–C), respectively. Compared to the other fiber-based commercial 
dressings, the present lyophilized [CEL + CS] composites have comparable levels of whole blood 
absorption. In this study, whole blood was used instead of saline or prepared artificial transudate or 
exudate material because it was previously found that the types of dressings, including foam, alginates, 
gauze, hydrocolloids, and collagen absorb whole blood different from the other two artificial media.37 To 
be more consistent with the physiological environment of a wound, we chose to examine the 
absorptivity with whole blood. Terrill et al. also stated that a dressing that absorbs over 35 g/100 
cm2 would be good for bleeding wounds.22 
It is evident from Figure 1(A,B) that for all compositions, [CEL + CS] composites dried by lyophilizing 
absorb relatively higher amount of blood compared to those air-dried. Depending on composition, 
lyophilized composites absorb at least 2–6× more blood compared to those by air-dried composites. 
Absorption amount by the air‐dried [CEL + CS] composites are comparable to the commercial 
nonlyophilized dressings (Promogram and DuoDerm), all between 2 and 7 g/100 cm2. The lyophilized 
[CEL + CS] composites showed comparable results for absorption over time to the commonly used 
lyophilized dressings such as gauze, Aquacel, and Allevyn. Moreover, we found that the absorption 
values of the composites approached the absorption amounts of the standard gauze and the Allevyn 
dressing, which may be used for moderate to heavily bleeding wounds. In particular, 29, 40, and 50% 
chitosan lyophilized materials are more absorptive than the Aquacel dressing materials. It is known that 
the fibrous make-up of gauze can lead to an increase of inflammation and on removal can cause trauma 
to the wound viable tissues with associated pain. 
Of particular importance is the observation that all of the lyophilized [CEL:CS] composites did have rapid 
absorption rates, such that the amount of blood absorbed at 30 min and 24 h did not differ greatly. In 
contrast, the air‐dried [CEL:CS] composites did absorb at a slower rate. This finding is not insignificant 
and may be descriptive to what type of wound would benefit by a specific composite. 
The results presented clearly indicate that the blood absorption capability of the [CEL + CS] composites is 
comparable to those of commercial dressings, and that the composites have ability to maintain moisture 
balance for wound healing. Such ability is one of the most important factors in the development of a 
biodegradable and biocompatible novel wound dressing material. 
The [CEL + CS] composites developed for wound dressing material must help to promote wound healing 
by creating a moist microenvironment for proper tissue regeneration. The presence of fibroblasts is 
critical for healing and the interaction of the fibroblasts with the composites must promote cellular and 
collagen proliferation. Previous reports have shown that chitosan materials are nontoxic to fibroblasts.38-
40 It is expected that chitosan composites can play a role in physiological regeneration of tissue during 
the wound healing process. 
In this study we analyzed the morphology and the proliferation capabilities of adherent fibroblasts by 
examining morphology microscopically. Results of the morphological analysis in the short term (3 days) 
and long term (7 days) are shown in Figures 2 and 3, respectively. Adherent fibroblasts were seen in 
wells after 3 days compared to the control well. The 7 day images show healthy fibroblasts in wells 
containing all chitosan composites. The adherent cells in 0, 29, 40, 100, and 100% lyophilized (i.e., 
100%L) showed a typical morphology of an elongated body and more cells than the other wells. As 
shown, compared to the control well, the chitosan composites did exhibit proliferation. The data in this 
study supports the use of the modified chitosan composites and the continued development of the 
material for proper scaffolding during wound healing. 
 
Figure 2 Images (40×) of human fibroblast in the presence and absence of [CEL + CS] composites for 3 days. Only 
one composite is lyophilized (100%L); the rest are all air-dried. The experiment was performed in duplicate. 
 
Figure 3 Images (40×) of human fibroblast in the presence and absence of [CEL + CS] composites for 7 days. Only 
one composite is lyophilized (100%L), the rest are all air‐dried. The experiment was performed in duplicate. 
Proliferation and viability of fibroblasts (Figure 4) in the presence and absence of chitosan composites 
were measured by the MTS assay (see Materials). Similar to Fakhry et al.,41 our study shows the 
proliferation of fibroblasts over time (from 3 to 7 days) and in the presence of chitosan there is a slowing 
of growth and proliferation although the cells still maintain the proper morphology. These results are in 
contrast to previous studies with modified chitosan material showing a direct correlation between time 
of incubation and amount of proliferation.32, 40 Mori et al.42 theorized that materials with higher 
amounts of chitosan can inhibit growth of fibroblasts indirectly. Chitosan that can bind proteins and the 
fetal bovine serum used in the culture medium may be causing the caustic effect on the fibroblasts. Silva 
et al.40 more recently showed the ability to increase the host response of proliferation by fibroblasts 
with argon and nitrogen gases in plasma surface modification to their chitosan composites. 
 
Figure 4 Fibroblast viability was measured at 30 min (blue bars) and 24 h (red bars) by the conversion of MTS to a 
formazan product in the presence of active metabolic enzymes (see text for detailed information). The fibroblast 
metabolic activity was tested in the presence and absence of [CEL + CS] chitosan composites. Only one composite 
is lyophilized (100%L), the rest are all air‐dried. The experiments were performed in duplicate. [Color figure can be 
viewed in the online issue, which is available at wileyonlinelibrary.com.] 
The wound environment requires a proper balance between a multitude of factors including blood 
clotting, cellular survival, and tissue repair. Another benefit to proper wound healing is for the dressing 
material to possess anti-inflammatory activity, since proinflammatory cytokines (TNF‐α and IL‐6) are 
primary contributors to the inflammation associated with chronic wounds, which stalls and prevents 
them from proceeding into the proliferative phase of tissue regeneration. Consequently it is important 
to assess the biocompatibility of potential dressing materials. Accordingly, the [CEL + CS] composites 
were tested for anti‐inflammatory effects on macrophage derived TNF‐α and IL‐6. Results obtained, 
shown as images for TNF‐α (Figure 5) and quantitative for both TNF‐α and IL‐6 [Figure 6(A,B)] indicate 
that, similar to fibroblasts, monocytes were viable and able to differentiate into macrophages in the 
presence of the chitosan composites especially the 100% and 100%L material. 
 
Figure 5 Images of macrophages (40×) in the presence and absence of [CEL + CS] composites. Only one composite 
is lyophilized (100%L), the rest are all air‐dried. Monocytes were stimulated to become macrophages with PMA 
(see text for detailed information). The macrophages were cultured in the presence and absence of the [CEL + CS] 
composites. The experiments were performed in duplicate. 
 
Figure 6 Production of (A) TNF‐α and (B) IL‐6 by macrophages in the presence and absence of [CEL + CS] 
composites. Macrophages were cultured in the presence and absence of [CEL + CS] composites. Only one 
composite is lyophilized (100%L), the rest are all air‐dried. The amount of TNF‐α and IL‐6 produced by the 
macrophages was quantified by ELISA. 
Macrophages play an important role in our innate immunity to foreign substances, but can also mediate 
many responses when there is injury to tissue. These cells can phagocytize or engulf micro-organisms 
and cellular debris. They respond to tissue damage and infectious micro-organisms by phagocytosis and 
the release of chemical mediators known as cytokines. TNF‐α and IL‐6, proinflammatory cytokines are 
released and can help to regulate the immune response, but it can also lead to tissue damage to the 
host. Proinflammatory cytokines are upregulated during wound healing and regeneration. Mori et 
al.43 showed in a TNF receptor deficient wound mouse model that the time of healing and tissue 
regeneration was increased significantly. Their study concluded the need for an anti-inflammatory 
environment for accelerated wound healing. It has been noted that the over production of IL-6 has been 
associated with an increase in the production of scarring during wound healing.44 
The proinflammatory cytokines can be used as biomarkers for the proper differentiation of monocyte to 
macrophage and the inflammatory response of the macrophage.45-47 TNF‐α and IL‐6 were measured 
quantitatively to assess the inflammatory response in the presence of the chitosan composites and the 
results are shown in Figure 6(A,B), respectively. As shown, compared to the control macrophages (Cells 
alone + PMA), the 0, 29, and 40% chitosan composites showed no significant change in the amount of 
TNF‐α secreted within a 3 day period. The TNF‐α concentrations of 100% and 100% lyophilized chitosan 
composites were significantly lower, p = 0.05 and 0.01, respectively, than control showing a potential 
anti-inflammatory effect. The IL-6 levels were reduced considerable in the presence of 67, 100, and 
100% lyophilized chitosan material. This anti‐inflammatory effect with chitosan has been shown 
previously.47, 48 Oliveira et al.,49 showed that when chitosan was exposed to monocytes as the sole 
stimulant, after 10 days of incubation, the cytokine levels, including TNF‐α and IL‐6, reached anti-
inflammatory levels. Those results correlate with our study clearly indicate the anti-inflammatory effects 
of [CEL + CS] composites on PMA derived macrophages. 
In summary, we have successfully demonstrated that the novel [CEL + CS] composites, which we have 
previously synthesized using a green and totally recyclable method, possess all properties needed to be 
used effectively as a wound dressing. Specifically, the composites are antibacterial, hemostatic, 
biocompatible, good absorbent for anticoagulated whole blood, and are able to maintain moisture 
balance for wound healing. For example, the composites were found to inhibit the growth of both Gram 
positive and negative micro-organisms (including Escherichia coli (ATCC 8739), Staphylococcus 
aureus (ATCC 25923), methicillin resistant S. aureus (ATCC 33591), and vancomycin 
resistant Enterococcus faecalis(ATCC 51299)). They are nontoxic to fibroblasts, namely fibroblasts were 
found to grow and proliferate in the presence of the composites. They effectively absorb blood, and at 
the same rate and volume as commercially available wound dressings. The composites, in both air-dried 
and lyophilized forms, significantly inhibit the production of TNF‐α and IL‐6 by stimulated macrophages. 
Experiments are now in progress to evaluate wound dressing based on the composites. 
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